Gastrointestinal Cancer | Specialty

Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer

January 30th 2015

Use of Systemic Therapy for Resectable Pancreatic Cancer

January 30th 2015

Screening for Pancreatic Cancer in High-Risk Individuals

January 30th 2015

Molecular and Biologic Characteristics of Pancreatic Cancer

January 30th 2015

Questions Remain Regarding Combinations and Sequencing in pNETs

January 26th 2015

To gain insight into the unanswered questions surrounding the treatment of pNETs, OncLive interviewed Pamela L. Kunz, MD, Assistant Professor of Medicine/Oncology at Stanford University.

Multitargeted Drug Slows CRC as Third-Line Therapy

January 21st 2015

Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.

Dr. Muro on Pembrolizumab for Gastric Cancer

January 19th 2015

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Dr. Laura Dawson on HCC Challenges

January 19th 2015

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, talks about the challenges in treating hepatocellular carcinoma (HCC).

Monocyte-Targeting Agent Active in Locally Advanced Pancreatic Cancer

January 18th 2015

Almost half of patients with borderline resectable or locally advanced pancreatic cancer had objective responses to treatment with an investigational chemokine receptor antagonist.

Ramucirumab Improves Survival in HCC Subgroup

January 17th 2015

An analysis of patients with advanced hepatocellular carcinoma and elevated α-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.

Expanded NAPOLI-1 Analysis Further Characterizes MM-398 Benefit in Metastatic Pancreatic Cancer

January 17th 2015

Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.

Polymorphisms May Offer Clues to Treatment Outcomes in HCC

January 17th 2015

Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR), data from a retrospective study reported at the 2015 Gastrointestinal Cancers Symposium showed.

Adjusted Nab-Paclitaxel/Gemcitabine Regimen Less Toxic in Pancreatic Cancer

January 16th 2015

Changing the administration schedule for gemcitabine plus nab-paclitaxel from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer.

Dr. Kunz on the Impact of Lanreotide's Approval for Neuroendocrine Tumors

January 16th 2015

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.

Dr. Alexandria Phan on a CLARINET Study Subgroup Analysis

January 16th 2015

The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs.)

MET Inhibition Shows Some Promise in Advanced Gastroesophageal Cancer

January 16th 2015

Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.

Latest News & Insight: January 15, 2015

January 15th 2015

Updated KEYNOTE-012 Shows Activity for Pembrolizumab in Gastric Cancer

January 15th 2015

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

Dr. Cremolini on Frontline FOLFOXIRI Plus Bevacizumab in mCRC

January 15th 2015

Chiara Cremolini, MD, discusses findings from the phase III TRIBE trial that combined FOLFOXIRI with bevacizumab as a frontline treatment for patients with metastatic colorectal cancer.

Dr. Cutsem on Challenges of Targeted Therapies in Gastric Cancer

January 15th 2015

Eric Van Cutsem, MD, PhD of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the use of trastuzumab for the treatment of advanced HER2-positive gastric cancer.